ESALY Overview

Clinical Trial Results: Prothena Corporation announced results from its Phase 1 ASCENT clinical program, showing PRX012 as a potential monthly treatment for early symptomatic Alzheimer's disease with promising reductions in amyloid plaque.

Safety Concerns: The trial revealed higher rates of amyloid-related imaging abnormality-edema (ARIA-E) in patients treated with PRX012 compared to other FDA-approved anti-Aβ antibodies, raising concerns about its suitability for the studied population.

Workforce Reduction and Future Plans: Following a significant workforce reduction, Prothena plans to seek partnerships to advance PRX012 and its preclinical antibody PRX012-TfR, while discontinuing development of birtamimab after failing to meet trial endpoints.

Partnerships and Milestones: Prothena is set to receive up to $1.2 billion in milestone payments from Novo Nordisk, which is advancing coramitug, an amyloid depleter antibody initially developed by Prothena, into a Phase 3 program for ATTR amyloidosis.

Earnings Report: Biogen Inc. reported Q1 2025 adjusted earnings per share of $3.02, down from $3.67 a year ago but above the analyst consensus of $2.52, with total sales reaching $2.43 billion, exceeding expectations.

Revenue Trends and Guidance: The company anticipates a mid-single-digit percentage decline in total revenue for 2025, primarily due to falling multiple sclerosis product revenues, while new product launches may provide some offset; potential tariffs are not expected to significantly impact the financial outlook.

Approval of Lecanemab: The European Commission has approved Eisai and Biogen's amyloid-beta monoclonal antibody, Lecanemab, for treating mild cognitive impairment and mild dementia due to Alzheimer's disease under strict conditions, targeting specific patient demographics.

Market Impact and Sales Growth: Following the approval, Lecanemab has shown promising sales growth, with Biogen reporting approximately $87 million in global sales for the fourth quarter, while also facing competition from other Alzheimer’s treatments like Eli Lilly's donanemab.

Cobenfy's Market Potential: Bristol Myers Squibb anticipates that its newly approved schizophrenia drug, Cobenfy, will target the Alzheimer's market, which includes nearly 6 million patients in the U.S., with potential sales reaching up to $10 billion across various treatment uses.

Innovative Treatment Approach: Cobenfy could be the first drug specifically approved for Alzheimer's-related psychosis, offering a safer alternative to current atypical antipsychotics, and aims to alleviate symptoms like agitation and cognitive decline, significantly impacting patient care and quality of life.

FDA Acceptance of Lecanemab Application: The FDA has accepted the Biologics License Application for lecanemab-irmb (Leqembi) subcutaneous autoinjector for Alzheimer’s disease, with a PDUFA action date set for August 31, 2025. If approved, it will be the first home-administered treatment for Alzheimer's using an autoinjector.

Biogen's Acquisition Bid: Biogen has made an unsolicited bid to acquire Sage Therapeutics for $7.22 per share, which analysts view as a strategic move following the successful launch of Zurzuvae for postpartum depression.

Biogen's Stock Downgrade: Needham downgraded Biogen Inc from Buy to Hold due to limited catalysts and gradual sales growth for its Alzheimer's drug Leqembi, with projected revenues expected to remain flat or decline slightly until 2026.

Sales Projections and Market Challenges: Despite positive developments like EMA's recommendation for Leqembi, market expectations are high, and Biogen faces challenges in adjusting these expectations realistically, with Skyclarys and Zurzuvae also showing uneven sales growth.